Filter by:
What is the extent and nature of illicit drug use in prisons in France? What are the consequences and what responses are being provided?
This Théma report is devoted to the changes in the cannabis market in France, particularly in relation to the increase in the use of herbal cannabis.
This summary covers the main contributions from a collective OFDT publication entitled "Drogues et addictions, données essentielles" issued in April 2019.
Within the vast category of new psychoactive substances, 25x-NBOMe or NBOMe represents a group of compounds in the phenethylamine family, which mainly has a hallucinogenic and psychedelic effect in particular.
Within the framework of the ERANID project (European Research Area Network on Illicit Drugs), funded by the European Commission (EC), the OFDT carried out a Europe-wide survey in the six member countries of the consortium (Belgium, France, Italy, the Netherlands, Portugal, the United Kingdom) and at the level of the EC.
This 30-page document gives an estimate, between 210 000 and 250 000 problem drug users, based on data from 2006 and different methods.
These guidelines are the result of the work carried out within the framework of the Addictions Committee set up by the Ministry of Health in November 2006.
The aim of this document is to illustrate the different aspects of the situation of cannabis in France (consumption, market, risks and consequences, public policy, etc.).
This report tries to bring about some facts to answer three basic questions: how many people use drugs in France, as regards a single experience or a more regular one? Which users are in trouble? Which sanitary, social and legal damages are caused by these uses?
This manual presents the main results of a European project whose purpose is to develop a common model of an Early Information Function for Emerging Drug Phenomena. This function should allow to identify and understand early changes in drug uses or new drugs more quickly than by using standard monitoring systems.